Authors: Sharon Salt, Editor
Shanghai Green Valley Pharmaceuticals (China) has announced that the country’s regulatory agency has approved oligomannate (GV-971) as a new drug for the treatment of mild-to-moderate Alzheimer’s disease. This decision marks the first new drug approval for Alzheimer’s disease since 2003.
Oligomannate, which is an orally administered drug made from extracts of brown algae, is reported to:
- Recondition dysbiosis of gut microbiota;
- Inhibit the abnormal increase of intestinal flora metabolites;
- Modulate peripheral and central inflammation;
- Reduce amyloid protein deposition and tau hyperphosphorylation;
- Improve cognitive function.
Speaking about the study findings, Carol Routledge, who is Director of Research at Alzheimer’s Research UK (Cambridge, UK), commented: “While it might sound strange for a potential Alzheimer’s drug to come from seaweed, many naturally occurring compounds provide the basis for developing medicines.”